Subject: Important information regarding BI sponsored clinical trials

Dear Investigator,

Boehringer Ingelheim’s priority is the safety and wellbeing of all clinical trial participants. As a result of the COVID-19 crisis we have, therefore, made the decision to temporarily discontinue recruitment of new patients in ongoing clinical trials sponsored by Boehringer Ingelheim. We will continuously monitor the situation and update you when we determine that it is appropriate to resume recruitment into our clinical trials. During the interim period:

- no new patients shall be enrolled or screened
- for patients that have consented but not yet been randomized, please contact your Clinical Trial Manager (CTM) to discuss potential continuation of the subject in the trial
- patients who are already randomized into clinical trials should continue participation as appropriate

Furthermore, during the period of paused recruitment, no further sites will be initiated.

We will continue to take measures to safeguard the safety and wellbeing of our communities. As noted in our letter dated 12 March 2020, these may include, as applicable, implementation of remote monitoring, phone or remote patient visits, and, where necessary and feasible, direct shipment of trial medications to patients.

We wish you, your family, and colleagues a safe and healthy environment as we navigate this crisis. Boehringer Ingelheim takes this opportunity to thank you for your continued support.

In case you have questions, please contact the CTM or local Head of Clinical Operations.

Yours sincerely,

Dr. Mehdi Shahidi
Chief Medical Officer

Dr. Vijay Prabhakar
Head Global Clinical Operations

17 March 2020